SCHEMBL18740053

SCHEMBL18740053

COC(=O)c1c(C(F)(F)F)nn2c1N(Cc1cc(Cl)cc(Cl)c1)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CYP1A2 P05177 3/20 0.39
▸ CYP2C19 P33261 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PKM P14618 2/20 0.38
▸ PLAT P00750 1/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ PLA2G2A P14555 1/20 0.34
▸ GRN P28799 1/20 0.34
▸ SORT1 Q99523 1/20 0.34
▸ KCNH2 Q12809 2/20 0.34
▸ MRGPRX4 Q96LA9 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ GABRP O00591 1/20 0.33
▸ GABRD O14764 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB1 P18505 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18740180 0.94 MEN1 (0.39) MEN1KMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL18740092 0.92 PKM (0.45) MEN1KMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL18740218 0.90 MEN1 (0.44) MEN1KMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL18740430 0.88 CYP2D6 (0.43) MEN1KMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL18758571 0.87 PKM (0.41) MEN1KMT2ACYP1A2CYP2C19SMN1; SMN2
SCHEMBL18740240 0.87 MEN1 (0.45) MEN1KMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL18740174 0.87 GRN (0.39) MEN1KMT2ACYP1A2CYP2C19PLAT
SCHEMBL18740062 0.87 MEN1 (0.44) MEN1KMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL18740201 0.86 MEN1 (0.54) MEN1KMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL18739965 0.86 MEN1 (0.44) MEN1KMT2ACYP1A2CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434246-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2022-09-06 — — US disclosed
EP-3362454-B1 EP4 ANTAGONISTS EISAI R&D MAN CO LTD (JP) 2021-12-08 — — EP disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
CN-108473497-B EP4 antagonists 卫材R&D 管理有限公司 2021-09-10 — — CN disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
US-20180305362-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-10-25 — — US disclosed
EP-3362454-A1 EP4 ANTAGONISTS Eisai R&D Management Co., Ltd. (JP) 2018-08-22 — — EP disclosed
WO-2017066633-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434246-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 MEN1 1667/4885KMT2A 3284/4885CYP1A2 886/4885
US-20180305362-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 MEN1 1667/4885KMT2A 3284/4885CYP1A2 886/4885
US-10316040-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 MEN1 1667/4885KMT2A 3284/4885CYP1A2 886/4885
US-10941148-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 MEN1 1667/4885KMT2A 3284/4885CYP1A2 886/4885
US-20190315754-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 MEN1 1667/4885KMT2A 3284/4885CYP1A2 886/4885
US-20210347779-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 MEN1 1667/4885KMT2A 3284/4885CYP1A2 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback